{"id":2647,"date":"2026-04-25T10:50:00","date_gmt":"2026-04-25T08:50:00","guid":{"rendered":"https:\/\/www.phinc-group.com\/?p=2647"},"modified":"2026-05-12T11:59:58","modified_gmt":"2026-05-12T09:59:58","slug":"adc-pk-in-cancer-patients-using-pbpk-modeling","status":"publish","type":"post","link":"http:\/\/www.phinc-group.com\/en\/adc-pk-in-cancer-patients-using-pbpk-modeling\/","title":{"rendered":"Publication: Development of a PBPK Model for ADC (oncology)"},"content":{"rendered":"<div data-elementor-type=\"wp-post\" data-elementor-id=\"2647\" class=\"elementor elementor-2647\" data-elementor-post-type=\"post\">\n\t\t\t\t<div class=\"elementor-element elementor-element-3b685712 e-flex e-con-boxed e-con e-parent\" data-id=\"3b685712\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t\t\t<div class=\"elementor-element elementor-element-573b863 elementor-widget elementor-widget-text-editor\" data-id=\"573b863\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<h5 id=\"d34020917\" class=\"wp-block-heading\">Antibody-drug conjugates (ADCs) represent a promising anticancer approach. Although physiologically based pharmacokinetics (PBPK) modeling became essential in Pharmacometrics to characterize exposure in different tissues, very few PBPK models have been published for ADCs, none within the PK-Sim\/MoBi software.\u00a0<\/h5>\n<p><!-- \/wp:heading --><!-- wp:paragraph --><\/p>\n<p>To capture the pharmacokinetics (PK) of an anti-Claudin 18.2 ADC, a PBPK model was built in PK-Sim and MoBi and compared to observations from three clinical studies after intravenous (IV) administration in 109 patients with cancer.\u00a0<\/p>\n<p>The PK parameters were considered inaccurate if the predicted error ratios were outside the two-fold error range (0.5\u20132). In PK-Sim, we defined one PBPK model comprising three compounds (ADC, payload, and naked antibody), which were mechanistically linked.\u00a0<\/p>\n<p>This model captured the ADC PK profile. However, additional clearance mechanisms were essential to improve the fit of the ADC elimination phase. After integration of target-mediated drug disposition (TMDD) and deconjugation of the payload in MoBi, 3 parameters were optimized for each of the ADC and the payload (degradation rate constant and reference concentration of the target, deconjugation rate constant, lipophilicity, nonspecific hepatic clearance rate constant and passive renal clearance of the payload). The PK data were adequately captured for both observed compounds, with a predicted error ratio within the two-fold range:\u00a0<em>C<\/em><sub>max<\/sub>_<sub>ADC<\/sub>\u00a0(1.07\u20131.50),\u00a0<em>C<\/em><sub>max_Payload<\/sub>\u00a0(0.56\u20131.18), AUC<sub>0\u2212504h_ADC<\/sub>\u00a0(0.73\u20131.23) and AUC<sub>0-504h_payload<\/sub>\u00a0(0.77\u20131.37).\u00a0<\/p>\n<p>The \u201cparameter optimization\u201d of different parameters allowed accurately capturing the observed data for both ADC and payload in cancer patients for an anti-Claudin 18.2 ADC. This analysis paves the way for PBPK modeling of other ADCs currently in development.<\/p>\n<p><!-- \/wp:paragraph --><!-- wp:paragraph --><\/p>\n<p><!-- \/wp:paragraph --><\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-3b93afd e-flex e-con-boxed e-con e-parent\" data-id=\"3b93afd\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t\t\t<div class=\"elementor-element elementor-element-b009372 elementor-widget elementor-widget-button\" data-id=\"b009372\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"button.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<div class=\"elementor-button-wrapper\">\n\t\t\t\t\t<a class=\"elementor-button elementor-button-link elementor-size-sm\" href=\"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/10.1002\/psp4.70071\" target=\"_blank\" rel=\"nofollow\">\n\t\t\t\t\t\t<span class=\"elementor-button-content-wrapper\">\n\t\t\t\t\t\t\t\t\t<span class=\"elementor-button-text\">Read more<\/span>\n\t\t\t\t\t<\/span>\n\t\t\t\t\t<\/a>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>","protected":false},"excerpt":{"rendered":"<p>A first-in-class PBPK model for CLDN18.2-targeted ADCs using PK-Sim\u00ae and MoBi\u00ae. Read and discover the full article!<\/p>","protected":false},"author":2,"featured_media":2666,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[41],"tags":[],"service-associe":[],"class_list":["post-2647","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-expertise"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.0 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Publication : D\u00e9veloppement d&#039;un mod\u00e8le PBPK pour les ADC (Oncologie) - PhinC Group<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.phinc-group.com\/en\/adc-pk-in-cancer-patients-using-pbpk-modeling\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Publication : D\u00e9veloppement d&#039;un mod\u00e8le PBPK pour les ADC (Oncologie) - PhinC Group\" \/>\n<meta property=\"og:description\" content=\"A first-in-class PBPK model for CLDN18.2-targeted ADCs using PK-Sim\u00ae and MoBi\u00ae. Read and discover the full article!\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.phinc-group.com\/en\/adc-pk-in-cancer-patients-using-pbpk-modeling\/\" \/>\n<meta property=\"og:site_name\" content=\"PhinC Group\" \/>\n<meta property=\"article:published_time\" content=\"2026-04-25T08:50:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-05-12T09:59:58+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.phinc-group.com\/wp-content\/uploads\/2025\/07\/bannere-chiara-2.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"683\" \/>\n\t<meta property=\"og:image:height\" content=\"448\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Mohamed Taourirt\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Mohamed Taourirt\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.phinc-group.com\/adc-pk-in-cancer-patients-using-pbpk-modeling\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.phinc-group.com\/adc-pk-in-cancer-patients-using-pbpk-modeling\/\"},\"author\":{\"name\":\"Mohamed Taourirt\",\"@id\":\"https:\/\/www.phinc-group.com\/fr\/#\/schema\/person\/4c52ff6996589ff3ca1ec2882fc5dd0a\"},\"headline\":\"Publication : D\u00e9veloppement d&rsquo;un mod\u00e8le PBPK pour les ADC (Oncologie)\",\"datePublished\":\"2026-04-25T08:50:00+00:00\",\"dateModified\":\"2026-05-12T09:59:58+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.phinc-group.com\/adc-pk-in-cancer-patients-using-pbpk-modeling\/\"},\"wordCount\":267,\"publisher\":{\"@id\":\"https:\/\/www.phinc-group.com\/fr\/#organization\"},\"image\":{\"@id\":\"https:\/\/www.phinc-group.com\/adc-pk-in-cancer-patients-using-pbpk-modeling\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.phinc-group.com\/wp-content\/uploads\/2025\/07\/bannere-chiara-2.jpg\",\"articleSection\":[\"Expertise\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.phinc-group.com\/adc-pk-in-cancer-patients-using-pbpk-modeling\/\",\"url\":\"https:\/\/www.phinc-group.com\/adc-pk-in-cancer-patients-using-pbpk-modeling\/\",\"name\":\"Publication : D\u00e9veloppement d'un mod\u00e8le PBPK pour les ADC (Oncologie) - PhinC Group\",\"isPartOf\":{\"@id\":\"https:\/\/www.phinc-group.com\/fr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.phinc-group.com\/adc-pk-in-cancer-patients-using-pbpk-modeling\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.phinc-group.com\/adc-pk-in-cancer-patients-using-pbpk-modeling\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.phinc-group.com\/wp-content\/uploads\/2025\/07\/bannere-chiara-2.jpg\",\"datePublished\":\"2026-04-25T08:50:00+00:00\",\"dateModified\":\"2026-05-12T09:59:58+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.phinc-group.com\/adc-pk-in-cancer-patients-using-pbpk-modeling\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.phinc-group.com\/adc-pk-in-cancer-patients-using-pbpk-modeling\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.phinc-group.com\/adc-pk-in-cancer-patients-using-pbpk-modeling\/#primaryimage\",\"url\":\"https:\/\/www.phinc-group.com\/wp-content\/uploads\/2025\/07\/bannere-chiara-2.jpg\",\"contentUrl\":\"https:\/\/www.phinc-group.com\/wp-content\/uploads\/2025\/07\/bannere-chiara-2.jpg\",\"width\":683,\"height\":448},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.phinc-group.com\/adc-pk-in-cancer-patients-using-pbpk-modeling\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\/\/www.phinc-group.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Publication : D\u00e9veloppement d&rsquo;un mod\u00e8le PBPK pour les ADC (Oncologie)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.phinc-group.com\/fr\/#website\",\"url\":\"https:\/\/www.phinc-group.com\/fr\/\",\"name\":\"PhinC Group\",\"description\":\"Quantitative Pharmacology Solutions &amp; Modeling\",\"publisher\":{\"@id\":\"https:\/\/www.phinc-group.com\/fr\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.phinc-group.com\/fr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.phinc-group.com\/fr\/#organization\",\"name\":\"PhinC Group\",\"url\":\"https:\/\/www.phinc-group.com\/fr\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.phinc-group.com\/fr\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.phinc-group.com\/wp-content\/uploads\/2025\/01\/Icone-PhinC-New_white-600px.jpg\",\"contentUrl\":\"https:\/\/www.phinc-group.com\/wp-content\/uploads\/2025\/01\/Icone-PhinC-New_white-600px.jpg\",\"width\":600,\"height\":600,\"caption\":\"PhinC Group\"},\"image\":{\"@id\":\"https:\/\/www.phinc-group.com\/fr\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.phinc-group.com\/fr\/#\/schema\/person\/4c52ff6996589ff3ca1ec2882fc5dd0a\",\"name\":\"Mohamed Taourirt\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.phinc-group.com\/fr\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/fb6e28f32440aa3a88b3657037d3180a08ec0bd3b98a8c4e463d059c0af8bd42?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/fb6e28f32440aa3a88b3657037d3180a08ec0bd3b98a8c4e463d059c0af8bd42?s=96&d=mm&r=g\",\"caption\":\"Mohamed Taourirt\"},\"url\":\"http:\/\/www.phinc-group.com\/en\/author\/mtaourirt\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Publication : D\u00e9veloppement d'un mod\u00e8le PBPK pour les ADC (Oncologie) - PhinC Group","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.phinc-group.com\/en\/adc-pk-in-cancer-patients-using-pbpk-modeling\/","og_locale":"en_US","og_type":"article","og_title":"Publication : D\u00e9veloppement d'un mod\u00e8le PBPK pour les ADC (Oncologie) - PhinC Group","og_description":"A first-in-class PBPK model for CLDN18.2-targeted ADCs using PK-Sim\u00ae and MoBi\u00ae. Read and discover the full article!","og_url":"https:\/\/www.phinc-group.com\/en\/adc-pk-in-cancer-patients-using-pbpk-modeling\/","og_site_name":"PhinC Group","article_published_time":"2026-04-25T08:50:00+00:00","article_modified_time":"2026-05-12T09:59:58+00:00","og_image":[{"width":683,"height":448,"url":"https:\/\/www.phinc-group.com\/wp-content\/uploads\/2025\/07\/bannere-chiara-2.jpg","type":"image\/jpeg"}],"author":"Mohamed Taourirt","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Mohamed Taourirt","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.phinc-group.com\/adc-pk-in-cancer-patients-using-pbpk-modeling\/#article","isPartOf":{"@id":"https:\/\/www.phinc-group.com\/adc-pk-in-cancer-patients-using-pbpk-modeling\/"},"author":{"name":"Mohamed Taourirt","@id":"https:\/\/www.phinc-group.com\/fr\/#\/schema\/person\/4c52ff6996589ff3ca1ec2882fc5dd0a"},"headline":"Publication : D\u00e9veloppement d&rsquo;un mod\u00e8le PBPK pour les ADC (Oncologie)","datePublished":"2026-04-25T08:50:00+00:00","dateModified":"2026-05-12T09:59:58+00:00","mainEntityOfPage":{"@id":"https:\/\/www.phinc-group.com\/adc-pk-in-cancer-patients-using-pbpk-modeling\/"},"wordCount":267,"publisher":{"@id":"https:\/\/www.phinc-group.com\/fr\/#organization"},"image":{"@id":"https:\/\/www.phinc-group.com\/adc-pk-in-cancer-patients-using-pbpk-modeling\/#primaryimage"},"thumbnailUrl":"https:\/\/www.phinc-group.com\/wp-content\/uploads\/2025\/07\/bannere-chiara-2.jpg","articleSection":["Expertise"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.phinc-group.com\/adc-pk-in-cancer-patients-using-pbpk-modeling\/","url":"https:\/\/www.phinc-group.com\/adc-pk-in-cancer-patients-using-pbpk-modeling\/","name":"Publication : D\u00e9veloppement d'un mod\u00e8le PBPK pour les ADC (Oncologie) - PhinC Group","isPartOf":{"@id":"https:\/\/www.phinc-group.com\/fr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.phinc-group.com\/adc-pk-in-cancer-patients-using-pbpk-modeling\/#primaryimage"},"image":{"@id":"https:\/\/www.phinc-group.com\/adc-pk-in-cancer-patients-using-pbpk-modeling\/#primaryimage"},"thumbnailUrl":"https:\/\/www.phinc-group.com\/wp-content\/uploads\/2025\/07\/bannere-chiara-2.jpg","datePublished":"2026-04-25T08:50:00+00:00","dateModified":"2026-05-12T09:59:58+00:00","breadcrumb":{"@id":"https:\/\/www.phinc-group.com\/adc-pk-in-cancer-patients-using-pbpk-modeling\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.phinc-group.com\/adc-pk-in-cancer-patients-using-pbpk-modeling\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.phinc-group.com\/adc-pk-in-cancer-patients-using-pbpk-modeling\/#primaryimage","url":"https:\/\/www.phinc-group.com\/wp-content\/uploads\/2025\/07\/bannere-chiara-2.jpg","contentUrl":"https:\/\/www.phinc-group.com\/wp-content\/uploads\/2025\/07\/bannere-chiara-2.jpg","width":683,"height":448},{"@type":"BreadcrumbList","@id":"https:\/\/www.phinc-group.com\/adc-pk-in-cancer-patients-using-pbpk-modeling\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/www.phinc-group.com\/"},{"@type":"ListItem","position":2,"name":"Publication : D\u00e9veloppement d&rsquo;un mod\u00e8le PBPK pour les ADC (Oncologie)"}]},{"@type":"WebSite","@id":"https:\/\/www.phinc-group.com\/fr\/#website","url":"https:\/\/www.phinc-group.com\/fr\/","name":"PhinC Group","description":"Quantitative Pharmacology Solutions &amp; Modeling","publisher":{"@id":"https:\/\/www.phinc-group.com\/fr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.phinc-group.com\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.phinc-group.com\/fr\/#organization","name":"PhinC Group","url":"https:\/\/www.phinc-group.com\/fr\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.phinc-group.com\/fr\/#\/schema\/logo\/image\/","url":"https:\/\/www.phinc-group.com\/wp-content\/uploads\/2025\/01\/Icone-PhinC-New_white-600px.jpg","contentUrl":"https:\/\/www.phinc-group.com\/wp-content\/uploads\/2025\/01\/Icone-PhinC-New_white-600px.jpg","width":600,"height":600,"caption":"PhinC Group"},"image":{"@id":"https:\/\/www.phinc-group.com\/fr\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/www.phinc-group.com\/fr\/#\/schema\/person\/4c52ff6996589ff3ca1ec2882fc5dd0a","name":"Mohamed Taourirt","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.phinc-group.com\/fr\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/fb6e28f32440aa3a88b3657037d3180a08ec0bd3b98a8c4e463d059c0af8bd42?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/fb6e28f32440aa3a88b3657037d3180a08ec0bd3b98a8c4e463d059c0af8bd42?s=96&d=mm&r=g","caption":"Mohamed Taourirt"},"url":"http:\/\/www.phinc-group.com\/en\/author\/mtaourirt\/"}]}},"_links":{"self":[{"href":"http:\/\/www.phinc-group.com\/en\/wp-json\/wp\/v2\/posts\/2647","targetHints":{"allow":["GET"]}}],"collection":[{"href":"http:\/\/www.phinc-group.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"http:\/\/www.phinc-group.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"http:\/\/www.phinc-group.com\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"http:\/\/www.phinc-group.com\/en\/wp-json\/wp\/v2\/comments?post=2647"}],"version-history":[{"count":24,"href":"http:\/\/www.phinc-group.com\/en\/wp-json\/wp\/v2\/posts\/2647\/revisions"}],"predecessor-version":[{"id":4907,"href":"http:\/\/www.phinc-group.com\/en\/wp-json\/wp\/v2\/posts\/2647\/revisions\/4907"}],"wp:featuredmedia":[{"embeddable":true,"href":"http:\/\/www.phinc-group.com\/en\/wp-json\/wp\/v2\/media\/2666"}],"wp:attachment":[{"href":"http:\/\/www.phinc-group.com\/en\/wp-json\/wp\/v2\/media?parent=2647"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"http:\/\/www.phinc-group.com\/en\/wp-json\/wp\/v2\/categories?post=2647"},{"taxonomy":"post_tag","embeddable":true,"href":"http:\/\/www.phinc-group.com\/en\/wp-json\/wp\/v2\/tags?post=2647"},{"taxonomy":"service-associe","embeddable":true,"href":"http:\/\/www.phinc-group.com\/en\/wp-json\/wp\/v2\/service-associe?post=2647"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}